Adagrasib plus cetuximab shows activity but does not improve survival in KRAS G12C-mutated metastatic colorectal cancer

Dr Josep Tabernero - Vall d'Hebron Institute of Oncology, Barcelona, Spain
Adagrasib plus cetuximab shows activity but does not improve survival in KRAS G12C-mutated metastatic colorectal cancer ( Dr Josep Tabernero - Vall d'Hebron Institute of Oncology, Barcelona, Spain )
13 Jul 2026

ctDNA MRD status predicts survival and adjuvant chemo benefit in resected colorectal liver metastas

Dr Kozo Kataoka - Hyogo Medical University, Nishinomiya, Japan
ctDNA MRD status predicts survival and adjuvant chemo benefit in resected colorectal liver metastas ( Dr Kozo Kataoka - Hyogo Medical University, Nishinomiya, Japan )
6 Jul 2026

Early ctDNA clearance linked to improved outcomes in KRAS G12C-mutant colorectal cancer

Dr Filippo Pietrantonio - Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Early ctDNA clearance linked to improved outcomes in KRAS G12C-mutant colorectal cancer ( Dr Filippo Pietrantonio - Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy )
10 Jun 2026

ASCO 2026: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada
ASCO 2026: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )
1 Jun 2026

Velzatinib demonstrates broad activity across KIT mutations in advanced gastrointestinal stromal tumours

Dr Neeta Somaiah - The University of Texas MD Anderson Cancer Center, Houston, USA
Velzatinib demonstrates broad activity across KIT mutations in advanced gastrointestinal stromal tumours ( Dr Neeta Somaiah - The University of Texas MD Anderson Cancer Center, Houston, USA )
1 Jun 2026

Optimal panitumumab–bevacizumab sequencing evaluated in RAS wild-type metastatic colorectal cancer

Dr Ramón Salazar - The University of Barcelona, Barcelona, Spain
Optimal panitumumab–bevacizumab sequencing evaluated in RAS wild-type metastatic colorectal cancer ( Dr Ramón Salazar - The University of Barcelona, Barcelona, Spain )
1 Jun 2026

Aspirin in stage III colorectal cancer shows no significant DFS benefit but favourable safety

Dr Atsuo Takashima - National Cancer Center Hospital, Tokyo, Japan
Aspirin in stage III colorectal cancer shows no significant DFS benefit but favourable safety ( Dr Atsuo Takashima - National Cancer Center Hospital, Tokyo, Japan )
1 Jun 2026

Structured exercise programme improves survival and reduces healthcare costs in colon cancer

Dr Kelvin K. Chan - Sunnybrook Odette Cancer Centre, Toronto, Canada
Structured exercise programme improves survival and reduces healthcare costs in colon cancer ( Dr Kelvin K. Chan - Sunnybrook Odette Cancer Centre, Toronto, Canada )
1 Jun 2026

Early-onset gastrointestinal cancers show more advanced disease and wider racial survival gaps

Dr Jessica Paulus - Ontada, Boston, USA
Early-onset gastrointestinal cancers show more advanced disease and wider racial survival gaps ( Dr Jessica Paulus - Ontada, Boston, USA )
1 Jun 2026

Yoga improves mood, fatigue, and insomnia in cancer survivors following treatment

Dr Karen Mustian - Wilmot Cancer Institute, Rochester, USA
Yoga improves mood, fatigue, and insomnia in cancer survivors following treatment ( Dr Karen Mustian - Wilmot Cancer Institute, Rochester, USA )
31 May 2026

Neoadjuvant chemoradiotherapy plus sintilimab improves pCR in resectable locally advanced oesophageal squamous cell carcinoma

Dr Xue-Feng Leng - Sichuan Cancer Hospital & Institute, Chengdu, China
Neoadjuvant chemoradiotherapy plus sintilimab improves pCR in resectable locally advanced oesophageal squamous cell carcinoma ( Dr Xue-Feng Leng - Sichuan Cancer Hospital & Institute, Chengdu, China )
30 May 2026

Bezuclastinib sunitinib combo shows promise in second-line GIST treatment

Dr Andrew J. Wagner - Dana-Farber Cancer Institute, Boston, USA
Bezuclastinib sunitinib combo shows promise in second-line GIST treatment ( Dr Andrew J. Wagner - Dana-Farber Cancer Institute, Boston, USA )
30 May 2026